Listed

Benitec Biopharma Inc.: Form 10-K for the period ended Jun 30, 2020

Filed with the SEC on Sep 23, 2020 and accepted by EDGAR at Sep 23, 2020, 16:50 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2019-07-01 to 2020-06-30$102.0kus-gaap:Revenues
Research and development12 months2019-07-01 to 2020-06-30$3.0mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2019-07-01 to 2020-06-30−$8.3mus-gaap:OperatingIncomeLoss
Net income12 months2019-07-01 to 2020-06-30−$8.3mus-gaap:NetIncomeLoss
Diluted EPS12 months2019-07-01 to 2020-06-30−$8.10us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2019-07-01 to 2020-06-30−$7.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2019-07-01 to 2020-06-30$95.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-06-30$9.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-06-30$10.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$11.6mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$1.3mus-gaap:Liabilities
Shareholders' equityAt period end2020-06-30$10.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-20-252381. Last ingested by Listed: Nov 14, 2026, 11:28 ET. Listed shows no prices and gives no investment advice.